Quick Answer
Corvus Pharmaceuticals, Inc. reported Diluted EPS of $0.53 per share (loss) for fiscal year 2025.
Corvus Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.53 | +48.0% |
| 2024 | -$1.02 | -82.1% |
| 2023 | -$0.56 | +37.1% |
| 2022 | -$0.89 | +13.6% |
| 2021 | -$1.03 | -415.0% |
| 2020 | -$0.20 | +87.4% |
| 2019 | -$1.59 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.12 | +80.0% | -20.0% |
| June 30, 2025 | -$0.10 | -42.9% | +23.1% |
| March 31, 2025 | -$0.13 | -8.3% | +78.3% |
| September 30, 2024 | -$0.60 | -400.0% | -757.1% |
| June 30, 2024 | -$0.07 | +50.0% | +41.7% |
| March 31, 2024 | -$0.12 | +29.4% | +0.0% |
| September 30, 2023 | -$0.12 | +62.5% | +14.3% |
| June 30, 2023 | -$0.14 | +22.2% | +17.6% |
- Corvus Pharmaceuticals, Inc. showed an increase of +48.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Corvus Pharmaceuticals, Inc.’s diluted eps has grown by 66.7% (from $1.59 per share (loss) to $0.53 per share (loss)).
- The most recent figure is from Corvus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: